This could be accounted for by the patient's immunodeficiency, chronic inflammation secondary to recurrent infections, and deletion of cathecol-O-methyltransferase (COMT) gene which is usually included in the hemizygous deletion, the product of which is involved in toxin metabolism. This evidence concerns the gene COMT and immunodeficiency disease.